Longeveron INC 10-Q quarterly reports

Longeveron Inc. reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq delisting notice.

Longeveron Inc. reported a widened net loss in Q2 2025, driven by increased R&D expenses for its clinical programs, while securing new funding to extend its cash runway into early 2026.

Longeveron Inc. reports a net loss of $5.0 million for Q1 2025 and expresses concerns about its cash runway, anticipating the need for additional funding by late Q3 2025.

Longeveron Inc. reports a net loss of $4.4 million for the third quarter of 2024, alongside increased revenue driven by clinical trials and manufacturing services.

Longeveron Inc. reports a reduced net loss and increased revenue for the second quarter of 2024, driven by clinical trial and contract manufacturing revenue, while also securing significant funding through warrant exercises and a direct offering.

Longeveron Inc. reported a net loss of $4.1 million for the first quarter of 2024, while highlighting progress in clinical trials and strategic initiatives.